@article{4c0ce5ec0181483fa3b3186910d901be,
title = "Racial disparities in patients with coronavirus disease 2019 infection and gynecologic malignancy",
abstract = "Background: Mounting evidence suggests disproportionate coronavirus disease 2019 (COVID-19) hospitalizations and deaths because of racial disparities. The association of race in a cohort of gynecologic oncology patients with severe acute respiratory syndrome-coronavirus 2 infection is unknown. Methods: Data were abstracted from gynecologic oncology patients with COVID-19 infection among 8 New York City area hospital systems. A multivariable mixed-effects logistic regression model accounting for county clustering was used to analyze COVID-19–related hospitalization and mortality. Results: Of 193 patients who had gynecologic cancer and COVID-19, 67 (34.7%) were Black, and 126 (65.3%) were non-Black. Black patients were more likely to require hospitalization compared with non-Black patients (71.6% [48 of 67] vs 46.0% [58 of 126]; P =.001). Of 34 (17.6%) patients who died from COVID-19, 14 (41.2%) were Black. Among those who were hospitalized, compared with non-Black patients, Black patients were more likely to: have ≥3 comorbidities (81.1% [30 of 37] vs 59.2% [29 of 49]; P =.05), to reside in Brooklyn (81.0% [17 of 21] vs 44.4% [12 of 27]; P =.02), to live with family (69.4% [25 of 36] vs 41.6% [37 of 89]; P =.009), and to have public insurance (79.6% [39 of 49] vs 53.4% [39 of 73]; P =.006). In multivariable analysis, among patients aged <65 years, Black patients were more likely to require hospitalization compared with non-Black patients (odds ratio, 4.87; 95% CI, 1.82-12.99; P =.002). Conclusions: Although Black patients represented only one-third of patients with gynecologic cancer, they accounted for disproportionate rates of hospitalization (>45%) and death (>40%) because of COVID-19 infection; younger Black patients had a nearly 5-fold greater risk of hospitalization. Efforts to understand and improve these disparities in COVID-19 outcomes among Black patients are critical.",
keywords = "coronavirus disease 2019 (COVID-19), gynecologic cancer, outcomes, racial disparities, severe acute respiratory syndrome-coronavirus 2 (SARS–CoV-2)",
author = "Lara, {Olivia D.} and Smith, {Maria J.} and Yuyan Wang and Roisin O{\textquoteright}Cearbhaill and Blank, {Stephanie V.} and Valentin Kolev and Caitlin Carr and Anne Knisely and Jennifer McEachron and Lisa Gabor and Eloise Chapman-Davis and Justin Jee and Julia Fehniger and Lee, {Yi Chun} and Sara Isani and Mengling Liu and Wright, {Jason D.} and Bhavana Pothuri",
note = "Funding Information: Roisin O{\textquoteright}Cearbhaill reports personal fees from Tesaro, GlaxoSmithKline (GSK), Regeneron, and Genentech USA, outside the submitted work; service as a noncompensated steering committee member for the PRIMA, Moonstone (Tesaro/GSK), and DUO‐O (AstraZeneca) studies, outside the submitted work; and institutional funding for clinical research from Celgene/Juno, Tesaro/GSK, Ludwig Cancer Institute, AbbVie, Regeneron, TCR2 Therapeutics, Atara Biotherapeutics, Marker Therapeutics, Syndax Pharmaceuticals, Genmab Therapeutics, Sellas Therapeutics, Genentech, Kite Pharma, and the Gynecologic Oncology Foundation, outside the submitted work. Stephanie V. Blank reports research collaborations with Roche/Genentech, Tesaro/GSK, Seattle Genetics, Merck, and AstraZeneca, outside the submitted work. Justin Jee reports a patent (16/686,663, 2020) licensed to MDSeq Inc. Jason D. Wright reports research funding from Merck and personal fees from Clovis Oncology, outside the submitted work. Bhavana Pothuri reports institutional support as Principal Investigator for industry‐sponsored trials from Tesaro/GSK, AstraZeneca, Merck, Genentech/Roche, Celsion and Clovis Oncology, outside the submitted work; personal fees from Tesaro/GSK, AstraZeneca, Eisai, Merck, and Mersana outside the submitted work; and noncompensated service on the PRIMA executive steering committee, outside the submitted work. The remaining authors made no disclosures. Funding Information: Roisin O{\textquoteright}Cearbhaill and Justin Jee were supported in part by the National Institutes of Health/National Cancer Institute cancer center support grant (P30 CA008748; Memorial Sloan Kettering Cancer Center Support Group). Publisher Copyright: {\textcopyright} 2020 American Cancer Society",
year = "2021",
month = apr,
day = "1",
doi = "10.1002/cncr.33335",
language = "English (US)",
volume = "127",
pages = "1057--1067",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "7",
}